Antidepressant-like effects of aniracetam in aged rats and its mode of action

Nakamura, Kazuo; Tanaka, Yushiro

doi:10.1007/s002130100849

Cited by 30 publications

(16 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in the open field activity test, crocin did not show a significant effect on total locomotion [34-37]. The studies have been reported that acute and chronic administration of imipramine (10 mg/kg) significantly reduced the immobility time and confirmed its antidepressant effects [40,41]. In our study, imipramine (10 mg/kg) like previous reports decreased the immobility time as compared with neutral control group.…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus

et al. 2014

View full text Add to dashboard Cite

BackgroundAntidepressants have been shown to affect levels of brain-derived neurotrophic factor (BDNF) and VGF (non-acronymic) whose transcriptions are dependent on cAMP response element binding protein (CREB) in long term treatment. The aim of this study was to verify the subacute antidepressant effects of crocin, an active constituent of saffron (Crocus sativus L.), and its effects on CREB, BDNF, and VGF proteins, transcript levels and amount of active, phosphorylated CREB (P-CREB) protein in rat hippocampus.MethodsCrocin (12.5, 25, and 50 mg/kg), imipramine (10 mg/kg; positive control) and saline (1 mL/kg; neutral control) were administered intraperitoneally (IP) to male Wistar rats for 21 days. The antidepressant effects were studied using the forced swimming test (FST) on day 21 after injection. Protein expression and transcript levels of genes in the rat hippocampus were evaluated using western blot and quantitative reverse transcription-polymerase chain reaction (qRT-PCR), respectively.ResultsCrocin significantly reduced the immobility time in the FST. Western blot analysis showed that 25 and 50 mg/kg of crocin increased the levels of CREB and BDNF significantly and dose dependently. All doses of crocin increased the VGF levels in a dose-dependent manner. Levels of p-CREB increased significantly by 50 mg/kg dose of crocin. Only 12.5 mg/kg crocin could significantly increase the transcript levels of BDNF. No changes in CREB and VGF transcript levels were observed in all groups.ConclusionsThese results suggest that crocin has antidepressant-like action by increasing CREB, BDNF and VGF levels in hippocampus.

show abstract

Section: Discussionsupporting

confidence: 75%

“…Different doses of crocin (12.5, 25, and 50 mg/kg) [28,39] were administered intraperitoneally (IP) for 21 days. Neutral and positive control groups received (IP) 1 mL/kg saline and 10 mg/kg imipramine, respectively [40,41]. Crocin and imipramine were dissolved in saline right before injections.…”

Section: Methodsmentioning

confidence: 99%

Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In this study, the TCA imipramine reduced immobility in the FST in both young/adult and aged mice. Similar findings were later reported by others Nakamura and Tanaka, 2001). Likewise, acute treatment with desipramine (IUPAC name: 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine; trade name: Abbreviations: TCAs, tricyclic antidepressants; SSRIs, selective serotonin reuptake Inhibitors; SNRIs, serotonin-noradrenaline reuptake inhibitor; HAMD, Hamilton Rating Scale for Depression; MADRS, Montgomery-Åsberg Depression Rating Scale.…”

Section: Effects Of Antidepressants In Aged Rodentssupporting

confidence: 92%

When ageing meets the blues: Are current antidepressants effective in depressed aged patients?

Felice

O’Leary

Cryan

et al. 2015

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

“…Non-NMDA receptor targets such as the AMPA glutamate receptor may be critical to ketamine’s rapid onset of action (Maeng et al 2008; Mathew et al 2008 b ). Compounds with AMPA receptor-potentiating properties have shown antidepressant-like effects in rodents (Black, 2005; Knapp et al 2002; Li et al 2001; Nakamura & Tanaka, 2001) and AMPA receptor subunit knockout mice demonstrated features of major depressive disorder (Chourbaji et al 2008). …”

Section: Discussionmentioning

confidence: 99%

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

Mathew

Murrough

Rot

et al. 2010

International Journal of Neuropsychopharmacology

263

268

View full text Add to dashboard Cite

The N-methyl-d-aspartate (NMDA) glutamate receptor antagonist ketamine may have rapid, albeit transient, antidepressant properties. This study in patients with treatment-resistant major depression (TRD) aimed to (1) replicate the acute efficacy of single-dose intravenous (i.v.) ketamine; (2) test the efficacy of the glutamate-modulating agent riluzole in preventing post-ketamine relapse ; and (3) examine whether pretreatment with lamotrigine would attenuate ketamine’s psychotomimetic effects and enhance its antidepressant activity. Twenty-six medication-free patients received open-label i.v. ketamine (0.5 mg/kg over 40 min). Two hours prior to infusion, patients were randomized to lamotrigine (300 mg) or placebo. Seventeen patients (65%) met response criterion (≥50% reduction from baseline on the Montgomery–Asberg Depression Rating Scale) 24 h following ketamine. Lamotrigine failed to attenuate the mild, transient side-effects associated with ketamine and did not enhance its antidepressant effects. Fourteen patients (54%) met response criterion 72 h following ketamine and proceeded to participate in a 32-d, randomized, double-blind, placebo-controlled, flexible-dose continuation trial of riluzole (100–200 mg/d). The main outcome measure was time-to-relapse. An interim analysis found no significant differences in time-to-relapse between riluzole and placebo groups [log-rank χ2 = 0.17, d.f. = 1, p = 0.68], with 80% of patients relapsing on riluzole vs. 50% on placebo. The trial was thus stopped for futility. This pilot study showed that a sub-anaesthetic dose of i.v. ketamine is well-tolerated in TRD, and may have rapid and sustained antidepressant properties. Riluzole did not prevent relapse in the first month following ketamine. Further investigation of relapse prevention strategies post-ketamine is necessary.

show abstract

Antidepressant-like effects of aniracetam in aged rats and its mode of action

Cited by 30 publications

References 50 publications

Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus

Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus

When ageing meets the blues: Are current antidepressants effective in depressed aged patients?

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

Contact Info

Product

Resources

About